Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive it has engaged leading contract research, development and manufacturing company Curia Global Inc to develop and manufacture GMP-grade IHL-216A, its proprietary inhaled drug for the treatment of concussion and traumatic brain injury. Curia will also generate data on the quality and stability of IHL-216A to support future regulatory filings, including a US Food and Drug Administration (FDA) pre-investigation new drug (IND) package and subsequent IND application.
Incannex agrees deal with Curia to scale-up manufacture of traumatic brain injury drug
